Across TCGA pan-cancer cohorts, RRN3 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of RRN3’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RRN3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RRN3 is over-expressed in tumor, although a few such as LSCC show the opposite, repressed pattern.
CCRCC and LSCC are the cancer types where RRN3 tumor–normal differential expression is most reproducible.